Publication of results from pivotal phase III study, PROTECT, of VBI’s prophylactic 3-antigen hepatitis B vaccine candidate.
PreHevbrio contains the S, pre-S2, and pre-S1 HBV surface antigens, and is the only approved 3-antigen HBV vaccine for adults in the U.S.
The approval of PreHevbrio was based on the results from two Phase III clinical studies, PROTECT and CONSTANT, data from which were published, respectively, in The Lancet Infectious Diseases in May 2021 and The Journal of the American Medical Association Network Open in October 2021.
The pivotal studies compared PreHevbrio to Engerix-B, a single-antigen HBV vaccine. Data from the PROTECT study showed that PreHevbrio elicited higher rates of seroprotection in all subjects age 18+ (91.4% vs. 76.5%), including in adults age 45+ (89.4% vs. 73.1%). The integrated safety analysis of both studies demonstrated good tolerability with no unexpected reactogenicity. The most common adverse events in all age groups were injection site pain and tenderness, myalgia, and fatigue, all which generally resolved without intervention in 1-2 days.
VBI expects to make PreHevbrio available in the U.S. in the first quarter of 2022, and has partnered with Syneos Health for the past two years to ensure commercial readiness.
See- VOLUME 21, ISSUE 9, P1197-1198, SEPTEMBER 01, 2021. "Three are better than one—increasing HBV seroprotection by a tri-antigenic vaccine":Florian van Bömmel, Thomas Berg. Published:May 11, 2021DOI:https://doi.org/10.1016/S1473-3099(20)30845-8. The Lancet Infectious Diseases.
See- "Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine. A Phase III Randomized Clinical Trial": Timo Vesikari, MD; Francisco Diaz-Mitoma, MD, PhD; for the CONSTANT Study Group; JAMA Net Open. 2021;4(10):e2128652. doi:10.1001/jamanetworkopen.2021.28652.
Related news and insights
GSK Australia is pleased to announce that the Therapeutic Goods Administration (TGA) has registered Zejula (niraparib) for the treatment of women with advanced high-grade ovarian, fallopian tube or primary peritoneal cancer following completion of first-line platinum-based chemotherapy.
Bristol-Myers Squibb K.K. announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and have either experienced disease progression on the last therapy or relapse after the last therapy.